Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
multi-characteristic opsin
technology4 mentionslast seen Nov 5, 2026
Proprietary genetically engineered synthetic opsin technology enabling optimized performance with high light sensitivity and fast kinetics.
Relationships 4
- MOGENRYdepends onmulti-characteristic opsin99% confidence4 sources
- Samarendra Mohantyauthoredmulti-characteristic opsin99% confidence2 sources
- Nanoscope Therapeuticsdevelopsmulti-characteristic opsin99% confidence2 sources
- multi-characteristic opsinapplies togeographic atrophy treatment96% confidence2 sources
Relationship
multi-characteristic opsinapplies togeographic atrophy treatment
96% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- newsPR NewswireNov 5, 2026Nanoscope Therapeutics Appoints Ophthalmology and Rare Disease Regulatory Leader Damon Daulerio as Executive Director of Regulatory Affairs
A Phase 2 program for MCO in geographic atrophy is expected to initiate in the near future
- newsPR NewswireSep 29, 2026Nanoscope Therapeutics to Present at Meeting on the Mesa 2026
A Phase 2 program for MCO in geographic atrophy is expected to start in 2026